ravulizumab

Ravulizumab is a humanized monoclonal antibody and long-acting complement inhibitor designed to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) in anti-acetylcholine receptor antibody-positive adults, and neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin 4 antibody-positive adults. It works by binding with high affinity to the terminal complement protein C5, inhibiting its cleavage into C5a and C5b, thereby blocking the formation of the membrane attack complex (C5b-9). This prevents complement-mediated cell lysis and reduces immune-mediated damage. Ravulizumab was engineered from eculizumab with modifications that extend its half-life, allowing for less frequent dosing while maintaining sustained inhibition of terminal complement activity[1][2][3][6].

Brand names

Ultomiris

Other names

ravulizumabALXN1210ALXN-1210ALXN 1210ravulizumab-cwvz